Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
SLN
Silence Therapeutics plc
Platform-based drug delivery (GalNAc-siRNA) enabling targeted delivery for siRNA therapies.
|
$322.63M |
$6.88
+8.35%
|
|
WALD
Waldencast plc
FDA-approved Obagi saypha MagIQ injectable gel indicates a dermal filler/medical device product line.
|
$322.19M |
$2.64
+3.13%
|
|
ALLO
Allogene Therapeutics, Inc.
Direct product category: off-the-shelf allogeneic CAR-T cell therapies (Allogene's core platform and pipeline).
|
$315.07M |
$1.42
+4.04%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$313.17M |
$5.31
+6.20%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$312.00M |
$2.90
+6.23%
|
|
SMLR
Semler Scientific, Inc.
QuantaFlo is a diagnostic device used to measure arterial blood flow for PAD, directly constituting Diagnostic Equipment.
|
$306.16M |
$20.68
+1.77%
|
|
NVEC
NVE Corporation
Medical devices & biometrics applications, including implantable sensors and collaboration with Abbott.
|
$303.15M |
$62.65
+0.93%
|
|
LRMR
Larimar Therapeutics, Inc.
Nomlabofusp is a recombinant fusion protein, i.e., a recombinant protein/enzyme therapeutic.
|
$302.13M |
$3.53
-3.81%
|
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
Lead programs are oral small-molecule therapeutics targeting NI&I indications.
|
$301.73M |
$10.77
+0.56%
|
|
CIA
Citizens, Inc.
Accident & health (A&H) / health insurance offerings are mentioned as part of the product mix.
|
$299.96M |
$5.94
+1.89%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$299.57M |
$20.84
+0.48%
|
|
SCPH
scPharmaceuticals Inc.
FUROSCIX is a cardiovascular drug (diuretic) approved for heart failure and CKD, representing SCPH's core product.
|
$299.33M |
$5.67
|
|
ENTA
Enanta Pharmaceuticals, Inc.
Enanta is actively developing antiviral small-molecule therapeutics targeting RSV, fitting the Antiviral Small-Molecule Therapeutics theme.
|
$298.01M |
$13.94
+2.05%
|
|
DRUG
Bright Minds Biosciences Inc.
Directly relates to development of neuropsychiatric/CNS therapeutics targeting serotonin receptors.
|
$295.33M |
$65.95
+0.64%
|
|
SNWV
SANUWAVE Health, Inc.
SANUWAVE directly manufactures and markets medical devices (UltraMIST and related wound-care technology) and biometrics for patient care.
|
$294.57M |
$34.25
-2.23%
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$292.74M |
$1.83
+2.51%
|
|
ACIU
AC Immune S.A.
Alzheimer's Disease Therapeutics – the company focuses on active immunotherapies and diagnostic assets for Alzheimer's disease.
|
$292.53M |
$2.92
+0.69%
|
|
SY
So-Young International Inc.
So-Young Clinic is a branded network of outpatient aesthetic centers, which is its core revenue driver.
|
$292.16M |
$2.88
+0.17%
|
|
TOI
The Oncology Institute, Inc.
Company operates community clinics and infusion suites (Outpatient/ASC Operators).
|
$291.73M |
$3.12
-1.11%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$289.91M |
$7.82
-1.01%
|
|
NAUT
Nautilus Biotechnology, Inc.
The hardware/assay suite functions as diagnostic-type equipment for proteomics analyses.
|
$286.71M |
$2.29
+4.34%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$285.70M |
$7.41
-1.98%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$285.33M |
$37.01
-1.10%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy is an implantable cardiac stimulation-based treatment for hypertension, aligning with Cardiology Devices.
|
$282.72M |
$5.21
-2.62%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$279.93M |
$2.32
+2.20%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$275.11M |
$1.90
+4.70%
|
|
WW
WW International, Inc.
WW operates WW Clinic and integrated weight health services, including clinical care delivery.
|
$274.64M |
$27.48
+2.77%
|
|
SPOK
Spok Holdings, Inc.
GenA alphanumeric pager represents a medical device hardware line under Medical Devices & Biometrics.
|
$273.86M |
$13.30
+1.53%
|
|
QSI
Quantum-Si incorporated
The company manufactures diagnostic-grade hardware instruments (Platinum/Proteus) used for proteomics analysis.
|
$273.37M |
$1.34
-0.37%
|
|
IMRX
Immuneering Corporation
Atebimetinib (IMM-1-104) is an oral small-molecule therapeutic in clinical trials.
|
$272.75M |
$7.51
+0.94%
|
|
FHTX
Foghorn Therapeutics Inc.
Clinical-stage biotech focused on oncology therapies targeting chromatin regulatory system (SMARCA2/BRG1, CBP/EP300, ARID1B degraders), a cancer-focused platform.
|
$271.91M |
$4.82
+2.12%
|
|
KRMD
KORU Medical Systems, Inc.
KRMD's core business is medical devices focused on patient-centric subcutaneous infusion systems (Freedom) and related components.
|
$268.16M |
$5.79
+10.29%
|
|
VMD
Viemed Healthcare, Inc.
Viemed operates as an in-home healthcare provider delivering home health and hospice services.
|
$266.85M |
$6.89
-2.13%
|
|
NNOX
Nano-X Imaging Ltd.
Core medical imaging devices and imaging systems produced by the company.
|
$266.27M |
$4.54
+0.55%
|
Showing page 20 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
